The Gates Foundation has outlaid $912m to prevent global deaths from AIDS, tuberculosis, and malaria, as drug and vaccine innovation features in a roadmap the foundation says is key to curbing childhood illness.

The donation is via the Global Fund to Fight AIDS, Tuberculosis and Malaria’s 2026-2028 replenishment, with the pledge delivered over three years. Bill Gates, co-founder and chair of the foundation, announced the near-billion-dollar commitment at the non-profit’s annual Goalkeepers event.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

“The choices they make now—whether to go forward with proposed steep cuts to health aid or to give the world’s children the chance they deserve to live a healthy life—will determine what kind of future we leave the next generation,” said Gates, who earlier this year pledged to give away almost his entire $200bn fortune by 2045.

He added: “I don’t expect most governments to suddenly restore foreign aid to historic levels, but I am an optimist, and I believe governments can and will do what’s needed to save as many children as possible.”

Without directly mentioning the country that has led the global cuts, Gates was likely directing his comments to the US Government. Under President Trump, the country paused all foreign assistance in January 2025. While some programmes have restarted, many remain in limbo – including foreign healthcare aid that meant the cessation of HIV, malaria and tuberculosis treatment services in low-income countries.

The biggest cull was the US Agency for International Development (USAID), which closed its doors in July 2025. Around $68bn was spent by the US on international aid in 2023, with USAID accounting for around $40bn of that total. Many plans in the President’s Emergency Plan for AIDS Relief (PEPFAR), which has become a major pillar in fighting the global HIV/AIDS response by providing testing services, antiretroviral treatment, and education programmes, have also been paused.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to a recent study by the Institute for Health Metrics and Evaluation (IHME), global development assistance for health dropped by 21% between 2024 and 2025, and is now at a 15-year low. If the current cuts hold, the institute says that decades of progress on child mortality could be reversed. The World Health Organization (WHO) has already signalled that decades of progress in tuberculosis gains are being curtailed due to funding cuts.

Pharma-focused roadmap

Working in tandem with the IHME, the Gates Foundation has created a roadmap which it says is key to saving millions of children and eradicating deadly paediatric diseases. Part of this is renewing investments in international initiatives such as the Global Fund and Gavi, the Vaccine Alliance. This helps access to life-saving medicines and treatments such as the recently approved long-acting HIV prevention drug Yeztugo (lenacapavir).  

The roadmap also calls for sustained R&D funding to help usher in innovative vaccines and drugs. Work is already underway to prevent mosquitoes from carrying parasites, along with the development of single-dose treatments to eradicate malaria. Meanwhile, more long-acting HIV drugs and prevention options, which would replace daily pills, could drive AIDS deaths down to single digits.

The roadmap also outlines the need for new maternal vaccines against respiratory syncytial virus (RSV) and group B streptococcus (GBS), which have the potential to protect babies from deadly respiratory illnesses.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now